Wedbush reaffirmed their outperform rating on shares of MacroGenics, Inc. (NASDAQ:MGNX) in a research note published on Monday morning. The firm currently has a $44.00 price objective on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Cowen and Company reaffirmed a buy rating on shares of MacroGenics in a research note on Friday, August 4th. SunTrust Banks, Inc. reaffirmed a buy rating and set a $26.00 price objective on shares of MacroGenics in a research note on Friday, September 1st. Morgan Stanley dropped their price objective on shares of MacroGenics from $22.00 to $21.00 and set an equal weight rating for the company in a research note on Monday, August 7th. Zacks Investment Research lowered shares of MacroGenics from a buy rating to a hold rating in a research note on Thursday, August 3rd. Finally, ValuEngine raised shares of MacroGenics from a strong sell rating to a sell rating in a research note on Friday, September 1st. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of $30.30.

MacroGenics (NASDAQ MGNX) opened at 16.91 on Monday. The firm has a 50-day moving average of $17.03 and a 200 day moving average of $18.43. MacroGenics has a one year low of $14.36 and a one year high of $32.68. The company’s market capitalization is $622.25 million.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.09). The firm had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The firm’s quarterly revenue was down 97.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.12 earnings per share. Equities research analysts predict that MacroGenics will post ($4.42) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “MacroGenics, Inc. (MGNX) Earns Outperform Rating from Wedbush” was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/14/macrogenics-inc-mgnx-earns-outperform-rating-from-wedbush.html.

Several institutional investors and hedge funds have recently modified their holdings of MGNX. Wasatch Advisors Inc. boosted its stake in shares of MacroGenics by 5,159.3% during the second quarter. Wasatch Advisors Inc. now owns 1,044,243 shares of the biopharmaceutical company’s stock valued at $18,285,000 after purchasing an additional 1,024,388 shares during the period. BB Biotech AG raised its holdings in shares of MacroGenics by 17.7% in the first quarter. BB Biotech AG now owns 2,260,000 shares of the biopharmaceutical company’s stock valued at $42,036,000 after acquiring an additional 340,000 shares in the last quarter. FMR LLC raised its holdings in shares of MacroGenics by 6.0% in the second quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock valued at $91,733,000 after acquiring an additional 295,553 shares in the last quarter. OppenheimerFunds Inc. raised its holdings in MacroGenics by 9.4% in the first quarter. OppenheimerFunds Inc. now owns 3,323,025 shares of the biopharmaceutical company’s stock worth $61,808,000 after purchasing an additional 286,018 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new position in MacroGenics in the first quarter worth about $4,514,000. 84.47% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.